Vagus Nerve Stimulators Market, by Product Type (Implantable Devices and External Devices), by Application (Epilepsy, Depression & Anxiety, Cluster Headache & Migraine, and Others (Crohn's disease, Dyskinesia, among others)), by End User (Hospitals, Speci

Vagus Nerve Stimulators Market, by Product Type (Implantable Devices and External Devices), by Application (Epilepsy, Depression & Anxiety, Cluster Headache & Migraine, and Others (Crohn's disease, Dyskinesia, among others)), by End User (Hospitals, Specialty Clinics, and Others (Research Institutions, Ambulatory Surgical Centers, among others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Vagus nerve stimulation (VNS) refers to a technique which involves stimulating the vagus nerve including electrical or manual stimulation. Right cervical VNS is effective for treatment of heart failure, while the left cervical VNS is an effective treatment for refractory epilepsy as well as resistant depression. Vagus nerve stimulation can be performed through the use of vagus nerve stimulators, which send mild, regular pulses of electrical energy to the brain via the vagus nerve. Vagus nerve stimulators can either be implanted or used as an external handheld device. Traditionally, a vagus nerve stimulator is surgically implanted under the skin on the chest, while a wire is threaded under the skin which connects the device to the left vagus nerve. Some of the side effects associated with use of vagus nerve stimulators include changes in voice/speech, throat or neck pain, headache, insomnia, indigestion, nausea or vomiting, impaired sense of touch, and others.

Market Dynamics

The increasing prevalence of neurological disorders such as depression, anxiety, epilepsy, migraine, and others, rising technological advancements in vagus nerve stimulators, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global vagus nerve stimulators market over the forecast period.

For instance, according to an article published by the Neuroepidemiology journal, a peer-reviewed scientific journal, in 2020, it is estimated that the incidence of epilepsy was 61.4 per 100,000 person-years in 2017 with higher incidence in low/middle-income countries (139.0 per 100,000 person-years) than in high-income countries (48.9 per 100,000 person-years).

Key features of the study:

• This report provides an in-depth analysis of the global vagus nerve stimulators market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global vagus nerve stimulators market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include LivaNova PLC, electroCore, Inc., SetPoint Medical Corporation, Beijing PINS Medical Co., Ltd., Parasym Ltd., Nervana, LLC, tVNS Technologies GmbH, BioControl Medical, NeurAxis, Inc., Soterix Medical Inc., MicroTransponder Inc., Boston Scientific Corporation, Cyberonics, Inc., EnteroMedics Inc., ReShape Lifesciences Inc., and Cerbomed GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global vagus nerve stimulators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vagus nerve stimulators market

Detailed Segmentation:

• Global Vagus Nerve Stimulators Market, By Product Type:
• Implantable Devices
• External Devices
• Global Vagus Nerve Stimulators Market, By Application:
• Epilepsy
• Depression & Anxiety
• Cluster Headache & Migraine
• Others (Crohn's disease, Dyskinesia, among others)
• Global Vagus Nerve Stimulators Market, By End User:
• Hospitals
• Specialty Clinics
• Others (Research Institutions, Ambulatory Surgical Centers, among others)
• Global Vagus Nerve Stimulators Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• LivaNova PLC*
• Company Overview
• Material Portfolio
• Financial Performance
• Key Highlights
• Market Strategies
• electroCore, Inc.
• SetPoint Medical Corporation
• Beijing PINS Medical Co., Ltd.
• Parasym Ltd.
• Nervana, LLC
• tVNS Technologies GmbH
• BioControl Medical
• NeurAxis, Inc.
• Soterix Medical Inc.
• MicroTransponder Inc.
• Boston Scientific Corporation
• Cyberonics, Inc.
• EnteroMedics Inc.
• ReShape Lifesciences Inc.
• Cerbomed GmbH

“*” marked represents similar segmentation in other categories in the respective section.